Sanegene Bio USA Inc
- Biotech or pharma, therapeutic R&D
SanegeneBio is an emerging biotech company developing innovative RNA interference (RNAi) therapeutics driven by the cutting-edge delivery technology. Founded in 2021, SanegeneBio was propelled by a team of industry-leading experts and has operations in both US and China. Since its inception, SanegeneBio has successfully established proprietary chemical modification platform, hepatic and extrahepatic delivery platforms targeting adipose, muscle and immune cells, enabling tissue or cell -specific delivery of a wide range of RNA therapeutics to efficiently knock down disease-causing genes.
Our focus at Bio will be looking for partners for five of our pipelines: SGB-C3 (Phase II, complement-related diseases), SGB-CFB (IND filed, complement-related diseases), SGB-INHBE (Preclinical, obesity), SGB-Lp(a) (Preclinical, ASCVD) and SGB-ALK7 (Preclinical, obesity). Please refer to the company assets page for more information of each asset.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}